Independent evaluation of tolerance of therapeutic plasma inactivated by amotosalen-HCl-UVA (Intercept™) over a 5-year period of extensive delivery

Vox Sanguinis

Volumn 109, Issue 4, 2015, Pages 414-416

  Bost, Vincent ^a   Chavarin, P ^a   Boussoulade, F ^a   Fabrigli, P ^a   Chabre, C ^a   Benamara, H ^a   Odent Malaure, H ^a   Legrand, D ^a   Cognasse, F ^a,b   Garraud, O ^b,c  

^a ETABLISSEMENT FRANÇAIS DU SANG   (France)

^b UNIVERSITÉ DE LYON   (France)

^c INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

Author keywords

Amotosalen; Haemovigilance; Pathogen reduction; Safety; Therapeutic plasma

Indexed keywords

AMOTOSALEN; FRESH FROZEN PLASMA; HLA ANTIBODY; HYDROCHLORIC ACID; FUROCOUMARIN DERIVATIVE;

ALLERGIC REACTION; ARTICLE; BLOOD EXAMINATION; BLOOD SAFETY; BLOOD TRANSFUSION; COMPARATIVE STUDY; HUMAN; HYPOTENSION; INFECTION CONTROL; PATHOGEN REDUCTION SYSTEM; PRIORITY JOURNAL; ULTRAVIOLET A RADIATION; ADVERSE EFFECTS; BLOOD STORAGE; EVALUATION STUDY; FRANCE; HYPERSENSITIVITY; PROCEDURES; STATISTICS AND NUMERICAL DATA; ULTRAVIOLET RADIATION;

BLOOD PRESERVATION; BLOOD TRANSFUSION; FRANCE; FUROCOUMARINS; HUMANS; HYPERSENSITIVITY; ULTRAVIOLET RAYS;

EID: 84944279073     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12300     Document Type: Article

References (10)

1. Hacquard M, Lecompte T, Belcour B, et al.: Evaluation of the hemostatic potential including thrombin generation of three different therapeutic pathogen-reduced plasmas. Vox Sang 2012; 102:354-361
2. Benjamin RJ, McLaughlin LS: Plasma components: properties, differences, and uses. Transfusion 2012; 52(Suppl 1):9S-19S
3. Mertes PM, Bazin A, Alla F, et al.: Hypersensitivity reactions to blood components: document issued by the allergy committee of the French medicines and healthcare products regulatory agency. J Investig Allergol Clin Immunol 2011; 21:171-178
4. Lozano M, Cid J, Muller TH: Plasma treated with methylene blue and light: clinical efficacy and safety profile. Transfus Med Rev 2013; 27:235-240
5. Bost V, Odent-Malaure H, Chavarin P, et al.: A regional haemovigilance retrospective study of four types of therapeutic plasma in a ten-year survey period in France. Vox Sang 2013; 104:337-341
6. Cazenave JP, Waller C, Kientz D, et al.: An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment. Transfusion 2010; 50:1210-1219
7. Funk MB, Guenay S, Lohmann A, et al.: Benefit of transfusion-related acute lung injury risk-minimization measures-German haemovigilance data (2006-2010). Vox Sang 2012; 102:317-323
8. Poisson JL, Riedo FX, AuBuchon JP: Acquired peanut hypersensitivity after transfusion. Transfusion 2014; 54:256-257
9. Hirayama F: Current understanding of allergic transfusion reactions: incidence, pathogenesis, laboratory tests, prevention and treatment. Br J Haematol 2013; 160:434-444
10. Savage WJ, Tobian AA, Savage JH, et al.: Scratching the surface of allergic transfusion reactions. Transfusion 2013; 53:1361-1371